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This thesis follows a career working with high consequence pathogens and the 
development of in vivo models of disease. I started as laboratory technician working 
with cell cultures and the production of viral antigens. However, it is when I moved to 
the tuberculosis (TB) research department that my interest in animal models took hold. 
It is here that I developed knowledge in the practical delivery of aerosols and the 
development of animal models to test vaccines, prophylaxis and interventions against 
disease. Whilst working in the TB department I completed a MSc. in Medical 
Microbiology at the University of Surrey with a thesis entitled ‘Oral delivery of a gelatin 
based BCG formulation to combat Mycobacterium bovis infection in a guinea pig model’.  
I moved to a US contracts team of scientists where I bought my expertise to develop 
animal models for a range of potential biothreat agents and play a key role in projects 
that at their peak employed 40+ staff with funding of over $59M. In this highly regulated 
environment, I led the modernisation and refinement of the organisations aerosol 
delivery systems, managed projects and successfully delivered on the research aims. 
This wealth of experience has placed me in the unique position of being able to lead the 
research and service delivery teams working at the maximum levels of containment for 




The natural route of human infection with many bacterial and viral diseases is via 
inhalation of droplet nuclei. Therefore, the production of bioaerosols in a controlled 
laboratory environment is deemed the most relevant route of infection for animal 
models. These models can be used to study, in a more natural context, the disease 
pathogenesis, or preclinical evaluation of the protective efficacy of vaccines or 
therapeutics against the challenge agent. Critical to the success of these animal models 
is the ability of the pathogenic microorganism to survive the stresses incurred whilst 
being generated and suspended as an aerosol. The ability of the pathogen to infect is 
dependent on aerosol droplet size, number of inhaled organisms and infectious dose. A 
well-characterised aerosol exposure system is critical for preclinical testing and 
pathogenesis studies. This thesis contains work, in the form of published papers, with a 
range of pathogens and animal models. These are the culmination of differing strategies 
to develop, characterise and qualify aerosol exposure systems at high containment, and 
the performance of preclinical testing and pathogenesis studies. The strategies 
employed have been instrumental in the approval of a new vaccine for smallpox, post-
exposure treatment regimens of anthrax and other diseases in the biodefence arena, 
and pre-clinical evaluation of vaccines against tuberculosis.  
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1.1. High containment 
In the United Kingdom (UK) the use of biological agents is controlled by primary 
legislation; the Health and Safety at Work Act, 1974 and the Animal Health Act, 1981. 
Supporting these are secondary regulations and approved codes of practice; the Control 
of Substances Hazardous to Health Regulations (COSHH) (HSE, 2013b), Management of 
Health and Safety at Work Regulations, 1999, Genetically Modified Organisms 
(Contained Use) Regulations (HSE, 2014), and Specified Animal Pathogens Order (SAPO), 
2008. In addition, The Advisory Committee on Dangerous Pathogens (ACDP) issues 
guidelines (HSE, 2018, HSE, 2015, HSE, 2013a) for working with pathogens to support 
the primary legislation. 
Human pathogens are categorised in the published, Approved List of Biological Agents 
(HSE, 2013a). Micro-organisms are classified into four hazard groups based on their 
pathogenicity, risk to laboratory workers, transmissibility to the community, and 
whether effective prophylaxis is available (HSE, 2013a) (Table 1). The hazard group of 
the pathogen determines the laboratory containment level that must be used. The 
example pathogens highlighted in bold in Table 1 are the pathogens that have been used 













An organism that may cause 
human disease and which may be a 
hazard to laboratory workers but is 
unlikely to spread to the 
community. Laboratory exposure 
rarely produces infection and 
effective prophylaxis or treatment 
is usually available 
Influenza A 




An organism that may cause severe 
human disease and presents a 
serious hazard to laboratory 
workers. It may present a risk of 
spread to the community but there 
is usually effective prophylaxis or 
treatment available. 









An organism that causes severe 
human disease and is a serious 
hazard to laboratory workers. It 
may present a high risk of spread 
to the community and there is 






The Specified Animal Pathogens Order classifies animal pathogens according to 
potential harm to susceptible animal species, the potential for the disease to spread 
from the laboratory and the subsequent economic impact if a release occurred (Defra, 
2015). Some micro-organisms are classified under both ACDP and SAPO schemes e.g. 
Bacillus anthracis - ACDP hazard group 3, SAPO hazard group 3 
High consequence pathogens are those that are classified in the UK as belonging to ACDP 
hazard groups 3 or 4. Infections caused by these pathogens frequently require co-
ordination at a national level e.g. the two cases of Monkeypox virus infection in the UK 
in 2018 which was managed as an enhanced incident in Public Health England (PHE) 
(Vaughan et al., 2018). 
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1.1.1. High containment facilities 
The requirements for the building, safe operation and maintenance of high containment 
facilities in the UK are based on the guidance and regulations of COSHH, ADCP and SAPO, 
and are reviewed in Table 2. Additionally, there are obligations relating to biosecurity 
under the Anti-Terrorism Crime and Security Act 2001 (ATCSA), which are implemented 
by the National Counter-Terrorism Security Office (NaCTSO). PHE also complies with 
United States (US) Federal Select Agent Program. 
The advanced level of engineering, associated management systems, training and 
emergency systems required to meet these containment specifications result in high 
building, operation and maintenance costs for these facilities.  
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2 3 4 
Workplace separated 
from other activities No Yes Yes 
Input and extract air 





Access restricted to 
authorised personnel 
only 
Yes Yes, and via 
airlock where RA 
dictates 
Yes, and via 
airlock 
Sealable for 
fumigation No Yes Yes 
Negative pressure 
cascade 
No Yes Yes, 
specified for SAPO 
(-50 to -75 Pa) 
Efficient vector 
control e.g. rodents 
and insects 
No, unless animal 
containment 
No, unless animal 
containment. 
Yes, if SAPO 
Yes 
Surfaces impervious 
to water and easy to 
clean, resistant to 
decontamination 
agents 
Yes, bench Yes, bench, walls 
and floor 
Yes, bench, walls, 
floor and ceiling 
Safe storage of 
biological agent 
Yes, secured for 
Schedule 5 
pathogens 





or alternative No Yes Yes 
Laboratory has own 
equipment 




Infected material and 
animals in 
containment 
Yes, where aerosol Yes, where 
aerosol 
Yes 
Incinerator Accessible Accessible On-site 
Effluent treatment 
plant No 
Yes, where RA 
dictates Yes 
Shower on exit No No, except where RA dictates Yes, for SAPO 
Autoclave Yes, in the building Yes, within suite Yes, within suite, 













1.2. Regulatory Framework and the use of animals in research 
1.2.1. The Animals (Scientific Procedures) Act 1986 
The Cruelty to Animals Act 1876 was the first UK law to regulate animal experimentation. 
It stood for 110 years until in 1986, The Animals (Scientific Procedures) Act (ASPA) was 
passed. The Act implements the requirements of European Union (EU) directive 2010/63 
governing the rules in relation to the care and use of animals in research to minimise 
the severity experienced by animals and to safeguard welfare.  
ASPA controls regulated procedures (defined as a procedure which may have the effect 
of causing the animal pain, suffering, distress or lasting harm) performed on protected 
animals (defined as any living vertebrate, other than man, and any living cephalopod), 
and does this by licencing on three levels; the person, the project, and the place.  
• Personal Licence: The licence permits an individual to carry out specified 
procedures on detailed animals. All procedures must be part of a programme of 
work authorised in a project licence. 
• Project Licence: A Project Licence is granted to a single, named individual. The 
holder group must possess the appropriate level of authority to manage the 
project. A Project Licence authorises the holder, to perform specific regulated 
procedures on specific animals at a specific place or places. The programme must 
be detailed and justified. There must be no alternative methods available, and 
the licence holder must demonstrate that the benefits clearly outweigh the likely 
impact on the animals’ well-being. 
• Establishment Licence: An Establishment Licence is granted to an individual 
responsible for institutional compliance at a place where regulated animal 
procedures are conducted. Every individual area is listed together with the 
species and type of use. 
ASPA is administered by the Secretary of State at the Home Office, who principally takes 
advice from a network of Home Office Inspectors. Inspectors have access to all facilities 
and can visit regularly, usually unannounced. They carry out detailed inspections and 
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provide advice on all matters relating to animal work and licencing thus ensuring high 
standards of compliance to the law and animal welfare are maintained. 
The system of regulation aims to ensure compliance to the 3Rs 
• Replacement: wherever possible, a scientifically satisfactory method not 
entailing the use of protected animals must be used instead of a regulated 
procedure. 
• Reduction: that whenever a programme of work involving the use of protected 
animals is carried out the number used must be reduced to the minimum 
without compromising the programmes’ objectives 
• Refinement: the breeding, accommodation and care of protected animals and 
the methods used in regulated procedures applied to them must be refined to 
eliminate, or reduce to the minimum any possible pain, suffering, distress or 
lasting harm to those animals. 
1.2.2. Good Laboratory Practice (GLP) 
Good Laboratory Practice is defined in the Organisation for Economic Co-operation and 
Development (OECD) Principles as “a quality system concerned with the organisational 
process and the conditions under which non-clinical health and environmental safety 
studies are planned, performed, monitored, recorded, archived and reported.” (WHO, 
2009).  
The US Federal Drug Administration (FDA) has rules for GLP in 21CFR58. Preclinical trials 
on animals in the US use these rules prior to clinical research in humans. Research in the 
US not conducted under these restrictions or research done outside US not conducted 
according to the OECD Guidelines (or FDA rules) might be inadmissible in support of a 
New Drug Application in the US. 
GLP is a managerial quality control system covering the process and the conditions 
under which non-clinical studies are planned, performed, monitored, recorded, 
reported and retained.  
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The Principles of GLP include: 
• Organization and Personnel 
o Management-Responsibilities 
o Study Director-Responsibilities 
o Principal Investigator-Responsibilities 
o Study Personnel-Responsibilities 
• Quality assurance program 
• Facilities 
o Test System Facilities 
o Facilities for Test and Reference Items 
o Archive facilities 
o Waste disposal 
• Equipment, Reagents and Materials 
• Test systems 
o Physical/Chemical 
o Biological 
• Test & Reference items 
o Receipt, handling, sampling and storage 
o Characterisation 
• Standard operating procedures 
• Performance of Study 
o Content of Study Plan  
o Conduct of Study 
• Reporting of results 
o Content of Final Report 
• Storage and retention of records and material 
It is important to differentiate between the formal, regulatory use of the term GLP and 
the general application of “good laboratory practices” in scientific investigations.  
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PHE Porton, is a member of the UK GLP Compliance Programme that has been inspected 
by the Medicine and Healthcare Regulatory Agency (MHRA) and issued with a Statement 
of GLP Compliance. 
1.2.3. The “Animal Rule” 
The use of animal models is sometimes criticised and are held up to unrealistic 
expectation, the term “model” implies that they are not intended to fully replicate 
human-pathogen interaction but rather provide an insight; their limitations include 
(National Research Council, 2011)  : 
• The lack of sufficient human data of the natural history of the disease; 
• Interspecies and intraspecies variability and the constraints imposed by working 
in biocontainment facilities; and 
• For some diseases, animal models have been shown to be unreliable surrogates 
for, or predictors of, efficacy and safety, as indicated by experience with product 
development and clinical trials. 
In the US regulations commonly known as the “Animal Rule” (21 CFR 314.600-650 for 
drugs; 21 CFR 601.90-95 for biologics) allow for the approval of products when human 
efficacy trials are not feasible. Its intended use is to protect public health and national 
security through the reduction/prevention of serious or life-threatening conditions 
caused by exposure to toxic chemical, biological, radiological, or nuclear substances. Its 
guidance  
To be considered for marketing approval under the Animal Rule, a product must meet 
the following 4 requirements (FDA, 2015) designed to alleviate criticism of animal 
models:  
• There is a reasonably well-understood pathophysiological mechanism of the 
toxicity of the substance and its prevention or substantial reduction by the 
product; 
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• The effect is demonstrated in more than one animal species expected to react 
with a response predictive for humans, unless the effect is demonstrated in a 
single animal species that represents a sufficiently well-characterized animal 
model for predicting the response in humans; 
• The animal study endpoint is clearly related to the desired benefit in humans, 
generally the enhancement of survival or prevention of major morbidity; and 
• The data or information on the kinetics and pharmacodynamics of the product 
or other relevant data or information, in animals and humans, allows selection 
of an effective dose in humans. 
It may appear that FDA approval of countermeasures may only be of benefit to US 
citizens, but this is not the case; investment the US government makes in this area is 
beneficial to other nations. Data generated through such may allow an improved 
evidence base for clinicians to manage public health emergencies, particularly in the 
event of a deliberate release. The animal models established are potentially also 
available for other drug and vaccine developers to use to assess the efficacy of their 
candidate countermeasures. FDA approval via the ‘Animal Rule’ allows 
countermeasures against priority pathogens to be purchased for the US government 
Strategic National Stockpile (SNS). Through the relationship between the UK and US 
governments, the SNS has been deployed in the UK in the recent cases of anthrax caused 
by B. anthracis contaminated heroin in injecting drug users. 
1.3. Aerosol delivery systems, biocontainment and animal model refinement 
The ACDP guidelines give very clear guidance on how the laboratory should operate but 
these only apply to work involving standard microbiology methods. Aerosol infection of 
animals with high consequence pathogens is non-standard and thus requires further 
robust risk assessment and may need additional regulatory approval. In addition, 
perhaps conflicting Quality and Home Office guidelines must be adhered to. The 
development of systems for both aerosol exposure and the subsequent housing of 
infected animals has evolved with changing regulations and has necessitated many 
discussions with the regulatory inspectors, subsequent design and testing of systems 
and equipment. 
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1.3.1. The history of aerosol delivery at Porton - the Henderson apparatus 
The Porton Down site has gone through many organizational changes since its initial 
development in the 1940s. One of the Centre’s primary roles has been to conduct 
fundamental research for the testing and development of new vaccines and to 
coordinate responses to emerging diseases. Aerosol models have always been a key 
part. 
An apparatus for the study of airborne infection was described by Henderson (1952). 
The apparatus was designed over several years to study the survival of bacteria 
suspended in the atmosphere, and the effect of such clouds of pathogenic bacteria on 
experimental animals.  
This equipment, later known as the Henderson apparatus, has evolved over time. A 
mobile unit was developed in the 1960s and is pictured in Figure 1 (Druett, 1969).  
  
Figure 1 - A mobile Henderson Apparatus 
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The key components in the design of the mobile Henderson Apparatus were: 
• Airflow management 
o A series of compressors, vacuum pumps, valves and critical orifices to 
provide controllable airflow and pressure regime. 
• Humidification 
o Provision of a humidifier and drier in which airflow can be mixed to create 
the desired aerosol conditions. 
• Nebuliser 
o Collison nebuliser 
• Spray tube 
o Enables the mix of generated aerosol and conditioned air 
• Animal exposure tube 
o Presentation of the aerosol to the animal 
• Aerosol sampling 
o Typically, a liquid impinger 
At this time there was no containment associated with the device apart from the use of 
personal respirators. However, with changing workplace safety regulations and the 
necessity for primary containment of the aerosol hazards the Henderson apparatus 
evolved further. Firstly, the equipment for controlling air flow and relative humidity was 
separated from the aerosol generating equipment, which was placed in a biosafety 
cabinet. This necessitated a separation between the spray tube and the animal exposure 
tube. It is with this configuration of equipment, named the contained Henderson 
apparatus that I commenced my career. 
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1.3.2. Design evolution of aerosol, biocontainment and animal model systems 
The development of animal model systems at PHE can be categorised into three main 
areas; the aerosol delivery system, biocontainment, and clinical parameter assessment. 
Throughout the evolution of our aerosol delivery systems there has been a desire to 
maintain the core components of the original Henderson apparatus, thus maintaining 
comparison with previous data. A timeline of this work is presented in Section 3. 
1.3.2.1. Evolution of the aerosol delivery system 
The success of inhalation studies using laboratory animals is a difficult challenge. The 
inhaled dose of an agent is one of the key factors to explain the response in the test 
subject (Dorato and Wolff, 1991). Four factors that impact on dose include 1) respiratory 
function of the test subject, 2) aerosol concentration, which is further complicated when 
studies use biological agents, 3) duration of the exposure, and 4) retention of the inhaled 
aerosol (Cheng and Moss, 1997).  
In its simplest form the dose can be expressed as  
𝐷𝐷 = 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 × 𝑀𝑀𝑀𝑀 × 𝑡𝑡𝐶𝐶𝑡𝑡𝑡𝑡 (× 𝑓𝑓) 
Where D = dose, Caero = concentration of agent in circulating aerosol, MV = respiratory 
minute volume or the volume of air inhaled in one minute, texp = time or duration of 
the exposure, f = aerosol deposition fraction as determined by animal species, depth of 
respiration and particle characteristics. The above equation assumes that the aerosol 
concentration and respiratory function are constant throughout the aerosol challenge 
(Hartings and Roy, 2004) 
There is often confusion when comparing results from different laboratories as dose can 
represent different things to different groups. The Association of Inhalation 
Toxicologists (AIT) Working Party recommended that delivered dose and deposited dose 
be adopted as standardised terminology (Alexander et al., 2008). The delivered dose is 
the amount of agent inhaled by or presented to the animal, and the deposited dose is 
the amount of agent deposited or retained in the lungs. What is most important is clarity 
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over what is meant by dose when presenting data. Some laboratories will apply an 
estimate of the deposition fraction typically 10–40% depending on the particle size and 
species (Alexander et al., 2008, Phillips, 2017). Our own estimate on the deposition 
fraction of B. anthracis in mice were calculated by culling animals immediately following 
aerosol challenge, removing the lung tissue, homogenising and enumerating the 
number of viable B. anthracis bacilli deposited. Approximately 20% of the presented 
dose was retained in the lung (Hatch et al., 2007, Hatch et al., 2009a).  
The transition of my research from Mycobacterium bovis and M. tuberculosis to 
biodefence agents required a different approach to the assessment of dose. 
Experiments with Mycobacterium spp. used an empirically derived aerosol dose based 
upon the relationship of experimental observation of lesions on the surface of the lung 
following exposure to an aerosol generated from differing concentrations of 
Mycobacterium spp.. Suspensions of 1.0E+06 and 1.0E+07 CFU/mL resulted in an 
average of 10 and 100 lesions, respectively, on the surface of the lung 4 weeks after 
challenge. It was assumed that 1 lung lesion formed from 1 CFU. The term “lung lesion–
forming unit” (LFU) was used to describe the deposited or retained dose (Williams et al., 
2000). 
Where possible, the aerosol concentration within the animal exposure chamber is best 
determined during the exposure rather than relying on historic data, to ensure any 
variations in aerosol generation efficiency are detected. Impaction, filtration, and 
impingement are three common sampling techniques used to separate and collect the 
bioaerosol. Two different types of liquid impinger, designed to operate over the 
respirable particle size range, were used over the course of the described studies, a SKC 
BioSampler (SKC Inc, PA, US) and the AGI-30 (Ace Glass, NJ, US). Two versions of the AGI-
30 were trialled operating at 6 and 12.5 L/min, the BioSampler operated at 12.5 L/min. 
In our hands, there was no statistical differences in the collection efficacy of the three 
liquid impingers (data not presented). 
Enumeration of the impinger samples taken from the exposure tube enabled a 
measurement of the number of viable organisms, in the circulating aerosol, to which an 
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animal was exposed. The next question to answer to estimate dose is the respiration 
rate of the animal. Although small animal plethysmography is available it is normal, for 
practical reasons, to estimate the volume of air inhaled. Allometric equations from 
empirical data between the relationship between body weight and respiratory volume 
provide an estimate of the volume inhaled in one minute i.e. minute volume (MV). 
MV (mL) = 2.1 x (Body weight in g)0.75   (Guyton, 1947) 
MV (L) = 0.499 x (Body weight in Kg)0.809   (Bide et al., 2000) 
The total of volume inhaled i.e. accumulated volume (AV) can be calculated by 
multiplying the MV and the duration or time of exposure (texp). 
 AV = MV x texp 
Predictive equations to estimate respiration will not capture animal to animal variation. 
The anaesthetic, individual metabolism, respiratory effects caused by the agent under 
investigation, or individual response to stress during exposure can all effect respiratory 
function, and for larger animals a potentially wide deviation from the predictive 
estimate (Hartings and Roy, 2004).  
The introduction of real-time plethysmography was critical to the development of our 
NHP models and minimising animal to animal variation of dose resulting from 
respiratory function. A head-out plethysmography chamber combined with 
BioSystemXA software (Buxco, UK) was installed. Pressure change, as the anaesthetised 
NHP’s abdomen expands and contracts are measured to derive respiration rate, tidal 
volume and accumulated volume. By limiting the aerosol exposure to a set accumulated 
volume of aerosol rather than the more usual timed exposure, we could considerably 
reduce the challenge dose variability between animals. 
Improved small animal restraint was incorporated into the aerosol system. Historically 
a box-type device was used in which the animal was held in place by neck restraint with 
the animal’s nose introduced into the exposure tube through a latex diaphragm. By its 
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nature this system could impair natural respiration. An improved tube design with an 
open caged head section was incorporated in which the animal had no tight restraint. 
The design benefitted animal welfare and handling, had less adverse effect on natural 
respiratory function, and could be sealed in the exposure tube aiding the control of air 
flow and pressure.  
Particle size is key to the successful delivery of an agent to the lung. Deposition is 
principally by inertial impaction, sedimentation, and diffusion. Large particles ( > 6 µm) 
are mainly deposited in the upper airway; small particles ( < 2 µm) are mainly deposited 
in the alveolar region (Darquenne, 2012). It is widely known that the region of the 
respiratory tract in which an agent is deposited can have an influence on both the 
infectious dose and the course of disease (Thomas et al., 2012). We have also shown 
this in our studies with Influenza A virus in cynomolgus macaques (Marriott et al., 2016). 
Intra-nasal challenge led to an infection that was confined to the nasal cavity. In 
contrast, a lower aerosol challenge dose produced an infection throughout the 
respiratory tract which was more aligned to the kinetics of infection displayed in human 
Influenza A virus infections. 
The Collison nebuliser was first described in the 1930s, it was modified by Druett to 
accommodate the use of smaller volumes; this Druett, MRE (Medical Research 
Establishment) design was described by May (1973), and has been the mainstay for 
aerosol studies at Porton since this time. The nebuliser uses compressed air to atomise 
a liquid; the produced droplets have a wide particle size distribution, the vast majority 
are recirculated to the fluid with only the smaller particles exiting the device (May, 
1973). The output of nebuliser is in the respirable range with a typical mean diameter of 
2 µm (range 0.5–7 µm)(Lever et al., 2000). 
To reconstruct the size profile for each challenge run an Aerodynamic Particle Sizer (APS) 
spectrometer, model 3321 (TSI Inc., MN, US) was installed to provide accurate count and 
size distributions for particles with aerodynamic diameters from 0.5 to 20 μm. The high 
concentration aerosols needed for our animal challenge models required dilution prior 
to measurement. The Model 3302A Diluter (TSI Inc., MN, US) was installed for a 
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calibrated dilution ratio of 100:1 at a total flowrate of 5L/min. Commercial versions of 
both a 3-jet and 6-jet versions of the modified MRE-type Collison nebuliser (BGI Inc, 
Waltham US) were investigated for use in the early development of the aerosol delivery 
system. Data showed that both versions of the nebuliser produced an aerosol in the 
desired respirable range, typically with a Mass Median Aerodynamic Diameter (MMAD) 
in the range of 1.5-2.0 μm, and a Geometric Standard Deviation (GSD) of approximately 
1.8-2.0. The ability to use either a 3-jet or 6-jet Collison nebuliser gave greater flexibility 
over the dose. 
From 2006 there was an expansion of the use of aerosol models in PHE. The 
manufacturing expertise of the Henderson apparatus was lost to PHE, so a critical 
examination of requirements was undertaken. Hartings and Roy (2004) described an 
automated bioaerosol exposure system (ABES); a microprocessor-driven inhalation 
platform providing data acquisition and control, with the inhalation chambers 
historically used at USAMRIID adapted from the Henderson apparatus (Henderson, 
1952). A version of the ABES was manufactured and purchased from Biaera 
Technologies, MD, USA.  
The Biaera system with AeroMP® Interface Module provided control and data 
acquisition of the airflow, humidity and pressure control supplied to the Collison 
nebuliser, impinger, spray and exposure tube previously described. In addition, the 
control software enabled integration of the APS and diluter into a single control and data 
management system. The combined systems were labelled the AeroMP-Henderson 
apparatus and provided much greater control and quality assurance to aerosol 
generation and delivery than was previously available. All air flow rates and pressures 
could be monitored by calibrated devices and alarmed throughout the aerosol delivery 
process. The real-time monitoring enabled potential issues to be immediately corrected, 
thus both increasing the quality assurance of the aerosol challenge process but also 
increasing animal welfare.  
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1.3.2.2. Evolution of biocontainment for aerosol studies and animal housing 
The contained Henderson apparatus enclosed the aerosol generation equipment within 
primary containment. However, the animal exposure was performed on a downdraft 
table still requiring the operator to use respiratory protective equipment. Post-exposure 
animals were housed within open cages in the Containment Level 3 (CL3) laboratory. In 
recent years one of the key requirements when using high consequence pathogens is 
the principle of primary containment.  
Animals cannot be housed in traditional class III microbiological safety cabinet (MSC). 
The high air-change rate and noise are incompatible with Home Office regulations. The 
solution was to design Flexible Film Isolators (FFI) to house the animals. These non-
standard devices enabled an equivalent operator protection factor to an MSC whilst 
meeting animal housing requirements. The first generation of FFI looked like a 
traditional MSC glove-box but were ergonomically poor. A half-suit design of FFI (Figure 
2) was quickly adopted and has become the mainstay of housing small animals infected 
with high consequence pathogens.  
Figure 2 – Small Animal Flexible Film Isolator; shown with guinea pig caging 
In addition to the animal housing, a FFI was designed to enclose the aerosol delivery 
apparatus with the existing Henderson control system (Figure 3).  
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Figure 3 - An aerosol challenge isolator with the original mobile Henderson control 
The introduction of the Biaera system with AeroMP® software interface enabled user 
control from within the FFI and provided (Figure 4). 
 
Figure 4 - A challenge isolator with the AeroMP-Henderson system. Insert displays the 
operator controlling the aerosol delivery from inside the isolator 
The development of a large animal system followed. Non-human primates (NHP) and 
rabbits cannot be readily housed within a FFI. A directional flow containment booth was 
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developed to offer primary containment (Figure 5). Animals are housed in Home Office 
compliant cages and conditions behind a Perspex panel. Air is directed from the room 
through weighted dampers in the panel and extracted to the rear through HEPA filters. 
A face velocity of a least 0.7 m/s is maintained when accessing animals through doors 
within the Perspex barrier thus maintaining operator protection. 
 
Figure 5 - A large animal directional flow containment system; pictured with NHP cages 
Large animal aerosol exposure is performed on a downdraft table whilst operators wear 
respiratory protective equipment (Figure 6). Rabbits are exposed via a traditional 
exposure tube; their snouts placed through a latex diaphragm into the aerosol flow. 
Non-human primates required a different set-up. A canine anaesthesia mask was 
modified to allow a flow through system that could be held on the animals’ face forming 
a seal. A head-out plethysmography chamber (Buxco, UK) was used to monitor the 
respiration of each sedated NHP throughout the aerosol challenge.  
20 
 
Figure 6 - AeroMP-Henderson NHP exposure system; Head-out plethysmography 
chamber and exposure mask 
The flexible bio-containment solutions that we have developed have been critical to the 
success of the animal models described in this submission but also provide ready 
solutions to emerging health problems. This has been evidenced by the swift transition 
of the directional flow containment booths to house ferrets for our pre-clinical 
evaluation of vaccines and therapeutics against SARS-CoV-2. 
1.3.2.3. Animal model refinement - assessment of clinical parameters 
To make the best use of the animals, improve the models and collect data on key clinical 
parameters, we have invested in several new technologies for both in-life and ex vivo 
analyses. These include implantable telemetry, clinical chemistry and haematology 
analysers, CCTV for remote welfare assessment, radiography, and the ability to use CT 
and PET-CT scanners. 
Implantable telemetry allows for the safe, continuous monitoring and recording of a 
wide range of physiological parameters in conscious, freely moving experimental 
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animals. These data can help in the understanding of pathogenesis, may provide 
information to identify appropriate humane endpoints before progression to severe 
disease, and in post exposure treatment models provide the indicator to begin 
treatment. Considerable effort and expense were required for the installation of this 
technology ranging from the design of caging systems to eliminate radio frequency 
interference, development of the surgical skills and qualification of the system. The 
original implants, D70-PCT (Data Sciences International (DSI), US) transmitted on a radio 
frequency requiring animals to be singly housed. An upgraded digital system with L11 
implants (DSI, US) was later installed which allowed NHPs to be group housed providing 
both an improvement in animal welfare and better data integrity. The implants 
measured body temperature, activity, heart rate, blood pressure and ECG. The 
conventional method for measuring respiratory rate via implantable telemetry is via a 
pressure sensor implanted into the pleural cavity via the serosal layer of the oesophagus. 
We demonstrated that respiration rate can be derived from a blood pressure signal 
reducing complexity of required surgery (Hatch et al., 2008a).  
Developed for our TB programme but recently of great value to our Covid-19 response 
is the ability for in-life CT scanning of NHPs. A considerable effort was required to enable 
this programme; from consultation with the HSE, design and testing (including crash 
tests) of a battery powered mobile FFI testing, and reassurance to the scanner providers. 
The solution, displayed in Figure 7, enables us to remove anaesthetised animals infected 
with HG3 agents such as M. tuberculosis or SARS-CoV-2 for the facility, obtain in-life 
scan, and return to the facility.  
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Figure 7 – Panel A depicts the mobile scanner outside our facility. Panel B displays the 
mobile FFI inside the scanning truck, and Panel C shows the FFI extension being 
inserted into the scanner. 
1.3.3. Qualification of the aerosol delivery system 
During aerosol model development and prior to the use of animals, the system 
parameters for each agent should be investigated and a standard aerosol protocol 
established. The use of agent specific parameters ensures that the presented dose can 
be controlled and that run to run variation is minimised. The spray factor (SF) can be 
used as a fundamental indicator to measure and assess the performance of the aerosol 
system over time. The SF is a unit-less ratio of the aerosol concentration to the starting 
concentration in the nebuliser. It is a function of the nebuliser, agent and system flow 
and describes the dilution that is to be expected during an aerosol experiment using a 
specific agent and aerosol system. If all components of the aerosol system are operating 











Where SF = spray factor, Caero = concentration of agent in the circulating aerosol, Cneb 
= concentration of agent in the nebuliser, Cimp = concentration of agent in the impinger 
sample, Vimp = volume of collection fluid in the impinger, Qimp = sample flow rate of 
the impinger, texp = time or duration of the aerosol exposure. 
The effect of relative humidity (RH) on the survival bacteria and viruses in an aerosol is 
a well-established although complicated relationship e.g. even bacteria with the same 
structural classification vary in their response to RH (Tang, 2009). For each agent the SF 
between low (50% RH) and high humidity (90%) was assessed. In our system RH had 
little effect on the viability of challenge agent due the short time in which the agent was 
in an aerosol between nebuliser and animal or impinger. However, in the configuration 
required to challenge NHPs a humidity of over 85% RH did result in a lower SF, likely due 
to greater losses due to impaction in the longer and less straight tubing required to 
deliver the aerosol to the animal. For consistency humidity was controlled at 65±5% RH. 
The dose presented to each animal is easily controlled by the nebuliser output and the 
concentration of agent within. This relationship must be examined and should be linear 
over the desired dose range, equating to a consistent SF. Figure 8 presents data from B. 
anthracis. The following calculations can be used to determine the necessary 
concentration of agent in the nebuliser in order to achieve a desired presented dose 






Figure 8 – Linear relationship between concentration of B. anthracis in the nebuliser 
and presented dose to a mouse. 
The aerosol delivery capability was a critical component in our animal studies. I initiated 
installation and operational qualification of the described AeroMP-Henderson 
apparatus and plethysmography system to the principles of GLP. The system, including 
both hardware and software components completed installation, operational and 
performance qualification. The refined aerosol delivery systems enabled PHE to 
continue to safely deliver a highly accurate and controllable dose of aerosolised 
biological agents to a variety of species. The equipment was unconditionally released 
for beneficial use.  
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1.4. Case Studies 
1.4.1. Mycobacterium tuberculosis 
Mycobacterium tuberculosis the causative agent of tuberculosis is one of the leading 
reasons of death from a single infectious agent worldwide. The WHO reported 1.5 
million people died from TB in 2018 (including 251 000 people with HIV). Worldwide an 
estimated 10 million people fell ill with TB. Multidrug-resistant TB (MDR-TB) remains a 
public health crisis and a health security threat with nearly 500 000 new cases resistant 
to the first-line drug, rifampicin (WHO, 2020). 
The current vaccine, Bacillus Calmette–Guérin (BCG), is only partially effective with 
efficacy ranging globally from 0% to 80% (Fine, 1995). Most infections do not have 
symptoms, in which case it is known as latent tuberculosis. The symptoms of active TB 
are a chronic cough with blood-containing mucus, fever, night sweats, and weight loss. 
TB is spread from person to person through aerosol transmission when people with 
pulmonary infection cough, sneeze or spit. The WHO estimates one-quarter of the 
world's population has latent TB. 5-15% of those with latent infections will eventually 
develop active TB, immune-compromised people are most at risk. 
PHE Porton, has been continuously conducting research into TB, and contributing to pre-
clinical testing of vaccines in animal models from the late 1990s. From 1999 to 2005 I 
was employed in this research, specifically in the development and subsequent use of 
inhalational animal models of TB. 
M. tuberculosis is exposed to different environmental conditions during disease, 
including intracellular growth in macrophages, extracellular growth in cavitary lesions 
and survival in anoxic granulomas (Danneburg 1994). Bacon et al. (2004) described the 
growth of M. tuberculosis H37Rv in a chemostat culture system under reduced oxygen 
tension. Using the guinea pig aerosol challenge model, we established that bacteria 
grown in a low-oxygen environment displayed a phenotype that was more infectious 
than aerobically grown cells. The infectivity assay was described in Williams et al. 
(2005c) and assessed the ability of a strain or phenotype to establish hematogenous 
spread from the lung to the spleen. Micro-array analysis highlighted 77 genes expressed 
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at higher levels in low oxygen which may contribute to increased virulence. Potential 
vaccine candidates were identified by examination of genes that were up- or down-
regulated in conditions that M. tuberculosis might encounter e.g. low oxygen or carbon 
starvation. Formulated as DNA vaccines a selection of candidates was evaluated in the 
guinea pig model (Vipond et al., 2006b, Vipond et al., 2006a) and provided protection 
against inhaled M. tuberculosis.  
As part of the EU TB Vaccine cluster funded by the EU Fifth Framework programme we 
contributed our guinea pig model to evaluate novel vaccines against tuberculosis with a 
view to provide promising candidates for clinical evaluation. This EU collaboration could 
provide comparative evaluations on vaccines that had previously demonstrated efficacy 
in animal models. Survival was used as the principal read-out of protection with 
additional data gathered from histopathology and mycobacterial count in the lung and 
spleen. Williams et al. (2005b), Williams et al. (2005a), Olsen et al. (2004), Agger et al. 
(2006) and Martin et al. (2006) describe this successful period of collaborations and pre-
clinical evaluation in which the aerosol guinea pig model of tuberculosis was key. 
Throughout my period in the TB research programme development of the aerosol and 
biocontainment continued. Containment systems for housing animals evolved; infected 
small animals were housed in FFIs and directional flow containment booths developed 
for NHPs. Chemostat cultures of M. tuberculosis were produced and aliquots frozen to 
provide a consistent challenge stock. Whist this approach has obvious advantages it was 
noted that the freeze/thaw cycle had an adverse effect on the ability of M. tuberculosis 
to survive the forces of the aerosol generation process (Clark et al., 2011). Procedural 
controls were utilised to negate this effect. 
An aerosol NHP model of tuberculosis was developed in rhesus and cynomolgus 
macaques. Systems for the safe delivery of the aerosol to the snout of the NHP were 
developed, replacing the traditional small animal exposure tube with a modified canine 
anaesthesia mask that allowed flow through of the aerosol and monitoring of the 
relative pressure. A head out plethysmography chamber enabled the real-time 
monitoring of NHP respiration and enabled a more accurate dose to be delivered across 
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the groups by limiting exposure to the aerosol to an accumulated volume rather than 
time. Routine in-life imaging in the form of radiography was established to refine clinical 
assessment of disease progression. Sharpe et al. (2009) describe the macaque model 
and the use of magnetic resonance imaging (MRI) and stereology to determine post-
mortem lung lesion volume. These studies highlighted the power of imaging 
technologies in a disease such as tuberculosis. We have invested considerable effort to 
incorporate in-life imaging of macaques by CT and recently PET-CT scans to fulfil our 3Rs 
obligation and thus reduce animal numbers and refine the clinical assessment of disease 
progression. 
The animal models that I helped establish and refine continue to contribute to the 
worldwide effort in pre-clinical evaluation of improved vaccines against TB. There 
currently 14 TB vaccine candidates in clinical trials, seven are based on subunits 
(mycobacterial fusion protein(s) in new adjuvant formulations and recombinant live-
attenuated or replication-deficient virus-vectored), and seven consist on whole-cell 
mycobacteria (based on inactivated/extracts of mycobacteria and on live attenuated 
mycobacteria)(Martin et al., 2020). Many of these vaccine candidates, or their pre-
cursors, have been successfully screened in our guinea pig or NHP TB challenge models.  
1.4.2. Yersinia pestis 
Yersinia pestis is a gram-negative bacterium and is the causative agent of plague. Plague 
is primarily a disease of small mammals which is transmitted between animals via their 
fleas, and can cause zoonotic disease by aerosol transmission or indirectly via arthropod 
vectors. Historically there have been human pandemics. Throughout history, there have 
been human pandemics, the greatest being during the Middle Ages where at least 25% 
of the population was killed (Prentice and Rahalison, 2007). Plague remains endemic in 
several areas worldwide, including China, central and southern Africa, and areas of Asia 
and South America (Williamson, 2009). Humans are extremely susceptible to plague 
with a route dependent aetiology. Pneumonic plague, caused by inhalation of droplets 
containing Y. pestis, has a fatality rate nearing 100% if treatment is not rapidly 
administered. 
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Killed whole cell vaccines for plague have been available for over one hundred years but 
there is no evidence that they provide protection against primary pneumonic plague 
(Williamson, 2009). Antibiotics such as streptomycin, chloramphenicol, tetracycline and 
newer options gentamicin and doxycycline have been used for the treatment of plague. 
Although Y. pestis has been shown to accept plasmids containing antibiotic resistant 
genes, it is very rare in nature (Butler, 2013). The high fatality rate of pneumonic plague 
combined with the potential to acquire antibiotic resistance makes Y. pestis a potential 
bioterrorist threat, and the production of a vaccine to protect against pneumonic plague 
is required. 
A robust and reproducible model of pneumonic plague was developed, in both BALB/c 
and Hsd:NIHS mice, with Y. pestis CO92 strain (biovar Orientalis, NR641) supplied by the 
Biodefence and Emerging Infections (BEI) Research Repository (US). Master and working 
stocks were prepared and characterised included microscopic staining (Wayson’s), 
colony morphology and purity checks, Congo red uptake on Congo red agar, multiple 
loci (5 target) PCR, 16S rRNA sequencing, and VNTR for genetic integrity checks. 
Preparation of Inoculum. A standardised protocol for the preparation of Y. pestis for 
aerosol challenge was developed. Briefly, a vial from the working stock was thawed and 
streaked onto Tryptic Soy Agar (TSA) and incubated at 26°C for 54 hours. Following 
successful subculture and purity check, the streak plate was used to seed Tryptic Soy 
Broth (TSB) and was incubated with orbital agitation at 26°C for 18 hours. Fresh TSB was 
added, and broths further incubated until an optical density of over 3 was measured at 
600nm wavelength (within approximately 3h). A four-target real time PCR was 
developed to confirm the presence of all three plasmids and the pgm virulence locus, to 
ensure genetic integrity and stability of the Y. pestis prior to use in each aerosol 
challenge study. A sample taken after the 18h TSB culture was analysed for the presence 
of genes; HmsF (chromosomal pgm locus), F1 (pMT1), Pst (pPCP1), and VAg (pCD1). 
Early developments of the aerosol challenge protocols were presented at the American 
Society of Microbiology (ASM), Biodefense and Emerging Diseases Research Meeting, 
Baltimore, US (Hatch et al., 2008b). In our system the median lethal dose (MLD) of Y. 
pestis in BALB/c mice was determined to be 5.0E+03 CFU (presented dose) with a time 
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to death of approximately 3-4 days following aerosol challenge. The aerosol systems 
used in these studies spanned the previously described refinement of the aerosol 
system, from the contained Henderson apparatus to the AeroMP-Henderson. At each 
change bridging studies were required to ensure equivalence. The desire to maintain 
the core components i.e. the Collison nebuliser, spray and exposure tubes and 
standardised conditions of 65% RH ensured the ease of transition.    
It has been shown that both humoral and cellular immunity are required for complete 
plague immunity (Anderson et al., 1997, Levy et al., 2011, Motin et al., 1994); however, 
antibodies against two natural virulence proteins F1 and V are associated with 
protection during a natural infection and have been shown to be protective in mouse 
models of pneumonic plague when given as recombinant proteins (Motin et al., 1994, 
Hill et al., 2006, Fellows et al., 2010). These (rF1 and rV) are the major constituents of 
new subunit plague vaccines (Williamson et al., 1997, Heath et al., 1998, Jones et al., 
2000, Quenee et al., 2011). With our characterised aerosol challenge model passive 
transfer studies in BALB/c mice showed a correlation between human IgG ELISA titre (to 
either rF1 or rV) and the mean time to death following aerosol challenge. However, it 
did not show the protection reported by Fellows et al. (2010). We next developed a 
model of pneumonic plague in Hsd:NIHS mice. Keeping all aerosol system and bacteria 
cultures parameter consistent there was no statistical difference between the 
susceptibility of either strain of mouse to an aerosolised challenge with Y. pestis, with 
equivalent MLD and time to death. 
The development of a pneumonic plague mouse models in BALB/c and Hsd:NIHS mice, 
and their subsequent use to test the Y. pestis subunit vaccine containing rF1 and rV by 
the passive transfer of unfractionated serum and plasma from immunised cynomolgus 
macaques and humans was described in Graham et al. (2014). This model of pneumonic 
plague and its use in passive transfer studies (using antibodies isolated from vaccinated 
individuals) may provide a tool to measure a correlate of protection against pneumonic 
plague and assist in the licensure of a new plague vaccine.  
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1.4.3. Burkholderia pseudomallei 
Burkholderia pseudomallei, the aetiological agent of melioidosis, causes a serious and 
often fatal disease in humans and animals (Titball et al., 2008). It is a soil-dwelling 
bacterium found in tropical and subtropical regions worldwide, and predominate in 
Southeast Asia and Northern Australia. Humans generally become infected through 
contact with polluted water; the bacteria entering the body through wounds, inhalation, 
or ingestion. B. mallei, the causative agent of Glanders (a disease that occurs primarily 
in horses, mules and donkeys) has been used as a biological weapon by several nations 
throughout recent history. Although B. pseudomallei has never been used as a biological 
weapon it is of concern. B. pseudomallei is resistant to many antibiotics, there is no 
licensed vaccine (Wiersinga et al., 2006), it is readily available in the environment, and 
can be aerosolised and transmitted by inhalation.  
Melioidosis results in approximately 89,000 deaths per annum, with diabetes a major 
risk factor (Wiersinga et al., 2006). Treatment for melioidosis involves an intensive 
intravenous antibiotic infusion (10-14 days) followed by 3-6 months of oral antibiotic 
therapy (Pitman et al., 2015). Given the long treatment regimen and inherent antibiotic 
resistance there is a desire for new medical countermeasures. The low natural 
occurrence of melioidosis makes traditional clinical trials difficult. We were awarded 
NIAID task order, N01-AI-30062, to develop and characterise both mouse and NHP 
aerosol infection models with a view to test the efficacy of medical countermeasures. 
A variety of mouse models of B. pseudomallei have been published with a range of 
bacterial strains, mouse species, and challenge routes (Lever et al., 2009, Conejero et 
al., 2011, Thomas et al., 2012, West et al., 2012, Lafontaine et al., 2013, Titball et al., 
2008, Massey et al., 2014). BALB/c mice appear to more sensitive to B. pseudomallei and 
are suitable to model acute infection, C57BL6 mice appear to better model a more 
chronic infection (Leakey et al., 1998, Hoppe et al., 1999, Tan et al., 2008, Liu et al., 
2002). We first sought to characterise the aerosol dose of and subsequent disease in 
BALB/c mice challenged with B. pseudomallei strain NCTC 13392. 
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B. pseudomallei strain NCTC 13392 was originally isolated from a septicaemic, diabetic 
patient with fatal melioidosis, in Khon Kaen, Thailand in 1996. The Mahidol University 
(Sirijad Hospital and Mahidol-Oxford Research Unit) assignment number was K96263. 
We obtained stocks from the NCTC and produced working and master banks. The use of 
this strain provides a cautionary tale on the quality assurance of challenge agents. It was 
not until after several years into our use of this strain in our work that sequencing 
demonstrated that the isolate differed from published genome of K96243. Subsequent 
investigation identified that although NCTC 13392 was received from the same 
laboratory in Thailand at the same time as K96243, it was unexpectedly a different strain 
(Sahl et al., 2013). Colony morphology variant sequences from our working stocks were 
reported by Vipond et al. (2013) and were deposited in the DNA Data Bank of Japan, 
ERX272106 (https://trace.ddbj.nig.ac.jp/DRASearch/experiment?acc=ERX272106), 
which matched that reported by Sahl et al. (2013). 
Early experiments defined the required aerosol conditions (challenge stock growth 
conditions, relative humidity, sampling medium, challenge dose) for a lethal infection in 
BALB/c mice. I presented posters detailing this work at ASM Aerobiology in Biodefense 
IV, Richmond, MD (Hatch et al., 2011a), ASM Biodefense and Emerging Diseases 
Research Meeting Baltimore, MD (Hatch et al., 2010a) and the associated ASM 
Burkholderia spp. Workshop Baltimore, MD (Hatch et al., 2010b). Aerosol challenge 
stock was generated in Luria Bertani Broth (LBB) incubated at 37°C, orbital shaking at 
175 rpm seeded from an overnight streak plate of NCTC 13392 on Luria Bertani Agar 
(LBA). Various harvest times were assessed early in the development of the aerosol 
model parameters ranging from a 4h mid-log, through 18h late-log to early stationary 
phase, and 24h stationary phase cultures. The spray factor of 4h and 18h cultures were 
respectively 10-fold and 5-fold lower than that of the stationary phase culture, indicating 
its greater resistant to the stress of the aerosolisation and sampling processes.  
The aerosol dose of B. pseudomallei (NCTC 13392) had a profound effect on the course 
of disease (Funnell et al., 2019). Initial studies focused on an acute disease and were 
designed with an endpoint at 14 days post-challenge.  A presented dose of 3.0E+04 CFU 
induced an acute lethal disease. However, it became evident that surviving animals had 
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a disease burden and subsequent studies were lengthened to 30 days post-challenge. A 
presented dose of 1.1E+02 CFU produced some clinical signs that appeared resolved but 
returned from day 5 onwards increasing slowly over the next 25 days. BALB/c mice 
exposed to 7.7E+01 CFU initially had mild clinical signs, which cleared and then returned 
from day 20 post-challenge, mimicking a chronic infection with bacteria found in 
multiple sites and abscesses, like that observed in human chronic disease (White, 2003). 
The described model could be used to evaluate vaccines and therapeutics in both acute 
and chronic forms of infection.  
The development of the NHP model was presented at the World Melioidosis 
Conference, Townsville, Australia (Hatch, 2013) and required a series of studies to assess 
the aerosolised dose of B. pseudomallei NCTC 13392 in cynomolgus and rhesus 
macaques. Post-challenge data was gathered via continuous telemetry, monitoring core 
parameters including temperature, respiration rate, blood pressure and activity. 
Animals were observed and health scores taken throughout the study. Blood was 
sampled for bacteriology, immunology and haematology analysis every three days. 
Upon necropsy, tissues were processed to paraffin blocks, sectioned at 3-5 µm, and 
stained with haematoxylin and eosin and examined microscopically. 
Rhesus macaques were more susceptible to aerosol challenge than cynomolgus 
macaques; in fact, we could not establish a disease in cynomolgus macaques following 
a high presented dose of 4.0E+04 CFU. This finding was in line with other researcher’s 
observations (personal communication). Rhesus macaques were chosen to test the 
efficacy of post-exposure treatment with oral delivery of co-trimoxazole following 
aerosol challenge with B. pseudomallei. 
Twelve Rhesus macaques were successfully challenged with an aerosol of B. 
pseudomallei (NCTC 13392) with a mean presented dose mean of 2.9E+04 CFU. In 
summary, in the rhesus macaque post-exposure prophylaxis with co-trimoxizole 
conferred significant protection against a lethal aerosol exposure to B. pseudomallei 
(NCTC 13392). The characteristics of the disease resembled acute human melioidosis 
with a rapid onset of clinical signs; pneumonia, fever 24-48 hours post-challenge, 
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dyspnoea 3-5 days post-challenge, leukocytosis 2-3 days post-challenge, high C-Reactive 
protein 2 days post-challenge and death 3-6 days post-challenge.  
1.4.4. Coxiella burnetii 
Coxiella burnetii is a Gram-negative intracellular bacterium and the etiological agent of 
Q fever. Q fever is a zoonotic disease that typically presents a self-limiting febrile disease 
but can progress to an atypical pneumonia, which can result in a life-threatening acute 
respiratory distress syndrome. C. burnetii can also cause a severe, and sometimes life-
threatening, chronic form of disease characterized by endocarditis or hepatitis (Brouqui 
et al., 1993). Q fever is found throughout the world, with the exception of New Zealand 
(Hilbink et al., 1993). C. burnetii has historically been developed as a biological weapon 
(Madariaga et al., 2003). It is stable in the environment, virulent, and is classed as a 
category B pathogen and bioterrorism agent by the CDC.  
A vaccine is available and licensed in Australia. Q-VAX® is a purified suspension of 
formalin-inactivated, C. burnetii prepared from the Phase I Henzerling strain of the 
organism grown in the yolk sacs of embryonated eggs. It has been given to “at-risk” 
workers (e.g. abattoir). Prior to immunisation, all potential vaccinees must be screened 
and have a serum antibody estimation and a skin test reported. If Q-VAX® is 
administered to those who are sensitised to Q fever antigens, serious hypersensitivity 
reactions can occur.  
Recovery from acute disease usually occurs within 2 weeks, or less following treatment 
with oral doxycycline. Delays in, or incorrect, diagnosis of Q fever often result in 
ineffective or inappropriate antibiotic treatment (Fournier et al., 1998). The chronic 
form of the disease is treated with a combination of doxycycline and chloroquine. 
Treatment periods are extensive from 18 months to 4 years (Raoult et al., 1999). 
Doxycycline-resistant strains have been observed in patients (Rouli et al., 2012). 
We developed and characterised a murine model of Q-fever and used it to assess the 
post-exposure efficacy of a liposome encapsulated ciprofloxacin. Studies are described 
in Norville et al. (2014). The model developed in A/J mice was non-lethal, so five 
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parameters were used to assess the disease; weight loss, clinical signs, organ weight 
(lung and spleen), bacterial burden and histopathology. Following aerosol challenge 
with axenically grown C. burnetii Nine Mile, A/J mice displayed clinical signs of disease 
from days 4-5 post-challenge. Clinical signs resolved within 14 days of infection which is 
similar to the acute disease observed in humans. Formulations of liposome-
encapsulated ciprofloxacin had previously been reported to improve antibiotic efficacy 
in Francisella tularensis, Mycobacterium avium, and Streptococcus pneumoniae in 
animal models (Oh et al., 1995, Conley et al., 1997, Ellbogen et al., 2003, Wong et al., 
2003). We demonstrated that ciprofloxacin for inhalation (CFI), a liposome-
encapsulated ciprofloxacin, allows effective pulmonary delivery, and showed significant 
improvements over doxycycline. In these development studies CFI was administered by 
intranasal inoculation. To better replicate the delivery that would be used in a human 
regimen, aerosol inoculation was investigated. The large volumes of material required 
by the Collison nebuliser made it unsuitable. Two alternative nebulisers were trialled; 
the LC Sprint star (Pari Medical Ltd, UK), compressed air driven producing particles of 
3.5 µm MMAD, and the Aerogen Pro (Aerogen, Ireland), vibrating plate producing 
particles of 3 µm MMAD. The LC Sprint star was successfully combined with our animal 
exposure system and proven as a delivery method to mice. 
1.4.5. Bacillus anthracis 
Bacillus anthracis is a Gram-positive, spore-forming bacterium that causes anthrax, a 
severe infectious disease of both animals and humans. An anthrax vaccine is available 
for humans deemed to be at high-risk of contracting anthrax; cell-free filtrates of the 
attenuated, non-capsulated Sterne strain of B. anthracis are licensed in both the UK and 
US for human use (Turnbull, 1991). The UK vaccine is made by alum-precipitation of 
antigen from in vitro Sterne cultures and is termed anthrax vaccine precipitated (AVP), 
to distinguish it from anthrax vaccine adsorbed (AVA) which is licensed for use in the US. 
Human infection is rare and usually occurs with low lethality via the cutaneous or 
gastrointestinal route. Human inhalational anthrax has a high mortality rate of 45-80% 
(Holty et al., 2006) with death occurring within days of exposure without subsequent 
treatment.  
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B. anthracis spores are highly resistant to extremes of temperature and humidity, and 
to treatment with chemical disinfectants; spores can remain viable for long periods in 
soil, and have been recovered from contaminated soil and animal remains after many 
decades (Wilson and Russell, 1964). These properties have led to anthrax being 
successfully developed as an effective biological weapon (Jernigan et al., 2002); anthrax 
weaponisation has been achieved by at least five national bioweapons programs: in the 
UK, Japan, the US, Russia and Iraq. 
An NIH-FDA Antibiotic Working Group recommended five antibiotics to be tested for 
prophylactic efficacy against inhalational anthrax, to increase therapeutic options and 
to address the needs of special populations e.g. children and pregnant women. The HHS 
Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) emphasised 
the needs of these special populations; however, these drugs required approval for use 
in the general population before seeking extended label indications for special 
populations. 
We were awarded two NIAID task orders; to test the efficacy of antibiotics in both a 
small animal and NHP models. The development of our mouse model spanned the 
refinement of our aerosol and containment systems. B. anthracis AMES (BEI resources 
NR-3838) was grown on solid medium over 21 days prior to harvesting and 
concentration by centrifugation. A median lethal dose was established in BALB/c mice. 
However, both the volume and quality of spores required for the large programme of 
work required we developed a small fed-batch fermenter production method. Using the 
source material, B. anthracis AMES (BEI resources NR-3838) we produced a fully 
characterised (real-time PCR, scanning electron microscopy, spore capsule staining 
(using malachite green stain) and demonstrating gamma bacteriophage and penicillin 
sensitivity) high titre spore stock to meet our development and testing needs. Due to 
security issues around the nature of this work, this methodology is not publicly available; 
however, the virulence of the resulting spore stock was presented at the American 
Society of Microbiology, Biodefense and Emerging Diseases Research Meeting, 
Baltimore (Hatch et al., 2009).  
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The recommended antibiotic (ciprofloxacin) against B. anthracis is based upon empirical 
treatments for sepsis, as there are no clinical studies of the treatment of anthrax in 
humans (Inglesby et al., 1999). The CDC updated their guidelines on treatment of post-
exposure inhalational anthrax, to include doxycycline and levofloxacin as well as 
ciprofloxacin (Hendricks et al., 2014). Ciprofloxacin has been investigated in many 
animal models of inhalational infection, ranging from mice, guinea pigs and rabbits 
(Altboum et al., 2002, Steward et al., 2004, Peterson et al., 2010) through to marmoset 
and rhesus macaques (Friedlander et al., 1993, Nelson et al., 2011, Fritz et al., 1995) and 
it has proved effective. To combat potential antibiotic resistance, continued research 
into the efficacy of different antibiotics or indeed different combinations of antibiotics 
is important. In addition, treatment with ciprofloxacin alone during the Amerithrax 
incident was seen to fail to protect 5 out of 11 individuals against inhalational anthrax. 
It is speculated that this failure was due to continued action of toxin in the absence of 
viable organisms (Twenhafel, 2010). A combination of antibiotics (e.g. bactericidal 
agents with protein synthesis inhibitors) may be more effective.  
Human inhalational anthrax has an incredibly rapid disease course, with death occurring 
within a few days of exposure without treatment. Following aerosol exposure to an 
inhaled dose ~ 1.2E+06 CFU B. anthracis (equating to 20 LD50) BALB/c mice will succumb 
to infection within 2-3 days. In Hatch et al. (2014) we describe our small animal model 
and the evaluation of levofloxacin, amoxicillin and co-amoxiclav which conferred 
significant protection (p < 0.001) from inhalational anthrax, whereas azithromycin and 
clarithromycin failed to protect. Two of these drugs, amoxicillin and co-amoxiclav, were 
selected for further evaluation.  
To support medical countermeasures against inhalational anthrax the FDA guidance 
recommended the use of an appropriate macaque model (FDA, 2002) and subsequent 
guidance and publications support the use of the African green, rhesus or cynomolgus 
macaque (FDA, 2015, Friedlander et al., 1993, Fritz et al., 1995, Vasconcelos et al., 2003, 
Twenhafel et al., 2007). We developed a cynomolgus model of inhalational anthrax for 
efficacy testing of post-exposure therapeutics. The pivotal studies in NHPs were 
required by the US to be conducted to GLP. Whilst not strictly within the remit of UK 
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regulatory GLP we gained approval from the MHRA to claim compliance. This 
necessitated a huge amount of equipment, system and assay, characterisation and 
validation. The model was used to successfully evaluate the post-exposure efficacy of 
amoxicillin and co-amoxiclav in terms of animal survival, bacterial burden, and time 
course of progression of diseases (including disease manifestations e.g. pathologic 
features and immune status). These data supported NIAID in their aim to increase the 
options for post-exposure prophylaxis indication for inhalational anthrax. 
The approach to prophylaxis and treatment of inhalation anthrax could be compromised 
by the release of B. anthracis carrying antibiotic resistance genes. Naturally occurring 
strains resistant to currently useful antibiotics have been reported (Altboum et al., 2002, 
Heine et al., 2007). In our BALB/c model, Negus et al. (2015) assessed the prophylactic 
and therapeutic potential of the poly-λ-D-glutamic acid (PDGA). This enzyme selectively 
removes the capsule from the surface of vegetative B. anthracis cell and prevented the 
emergence of signs of disease and death following a lethal inhalational dose of B. 
anthracis. 
1.4.6. Monkeypox 
Variola virus, the aetiological agent of smallpox, is highly contagious and causes disease 
with a high mortality rate (Chapman et al., 2010). Endemic smallpox was eradicated 
through a successful global immunization campaign by the World Health Organization 
(WHO) more than 30 years ago (Jacobs et al., 2009), with the final natural case of 
smallpox recorded in Somalia in 1977 (WHO, 2001). Since the eradication, vaccination 
against this pathogen has been discontinued, and so much of the world’s population 
currently lacks protective immunity (von Krempelhuber et al., 2010). Consequently, the 
use of variola virus as a biological weapon poses a current major public health threat. 
Other orthopoxviruses, for example, monkeypox, cowpox virus and a variety of vaccinia 
virus-like viruses (Bhanuprakash et al., 2010, Glatz et al., 2010, Rimoin et al., 2010, 
Trindade et al., 2007) can spread to humans by zoonotic infection and therefore also 
threaten public well-being. 
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The testing of new medical countermeasures against orthopoxviruses is a prime 
example of why the “Animal Rule” was developed. In the past, macaques were used in 
studies employing both variola virus and monkeypox virus in order to model the ordinary 
disease presentation of smallpox infection in people (Chapman et al., 2010). Since 
working with variola virus is both unethical and impossible given the obvious risks of 
reintroducing an eradicated disease, monkeypox virus infection in macaques has now 
become an acceptable surrogate model for human smallpox disease (Zaucha et al., 2001, 
Cann et al., 2012), provided an appropriate dose and route of challenge (Chapman et al., 
2010). 
A number of challenge routes have been described for macaques; subcutaneous (Nagata 
et al., 2014), intravenous (Earl et al., 2008, Earl et al., 2004, Buchman et al., 2010), 
intrabronchial (Stittelaar et al., 2005) and intratracheal (Goff et al., 2011). Fenner et al. 
(1988) stated the natural route of infection for smallpox in man is through close contact 
with an infected person via the oropharynx or nasopharynx. A deliberate release of an 
aerosol of smallpox or monkeypox would permit rapid dispersion across a large area. 
We sought to develop an aerosol challenge model of monkeypox in cynomolgus 
macaques. 
What little is known about susceptibility of cynomolgus macaques to monkeypox is 
based on animals sourced from other parts of the world than those from our breeding 
colony. It is understood that the susceptibility of a species to various agents can vary 
considerably, even with the same species, within a geographical sub-population. A 
stepwise approach was taken to first verify that we could repeat the results from an 
intravenous challenge. We sought to determine a dose of monkeypox that would 
produce a reproducible model of natural disease for us to fully characterise the model, 
compared with Smallpox in man, and eventually use it to assess protection.  
The data generated in our studies detailing clinical observations, viral loads, immune 
responses and pathological changes (Tree et al., 2015) supported and expanded on 
previous work using this infection model (Zaucha et al., 2001). The model displayed 
similarities to the clinical presentation of smallpox in humans (Fenner et al., 1988). Our 
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studies were reviewed by the US government and we were granted approval to use 
aerosolised monkeypox infection in cynomolgus macaques as a model for studying 
human pox infections utilising the FDA Animal Rule. 
The traditional smallpox vaccines used to eradicate smallpox are based on replicating 
vaccinia virus. Although highly efficacious, there are associated side effects ranging from 
mild and self-limiting to severe and life-threatening (Metzger and Mordmueller, 2007). 
Second generation smallpox vaccines (e.g. ACAM2000) produced in cell cultures from 
the Lister-Elstree or New York City Board of Health vaccinia virus strains are cleaner and 
appear as effective as the earlier vaccines. However, there are still contra-indications 
and it is estimated that 25% of the population would be at risk of developing 
complications (Kemper et al., 2002). Third-generation modified vaccinia Ankara (MVA) 
vaccines have been shown to be comparatively safe with none of the complications of 
first- and second-generation smallpox vaccines, especially for those with contra-
indications e.g. immune-compromised or atopic dermatitis (Kennedy and Greenberg, 
2009, Earl et al., 2004). 
IMVAMUNE® is a third-generation, MVA derived, vaccine manufactured by Bavarian-
Nordic (Martinsried, Germany). It has been supported through to licensure by the US 
Government, the National Institute of Allergy and Infectious Diseases (NIAID) for animal 
studies and subsequently the Biomedical Advanced Research and Development 
Authority (BARDA) clinical trials. The pivotal study in this programme of work assessed 
the protective efficacy of either one or two (prime-boost; administered 28 days apart) 
doses of IMVAMUNE® against an aerosol monkeypox virus challenge, protective efficacy 
was evaluated against the second-generation vaccine ACAM2000 (Hatch et al., 2013a). 
We showed that the use of a prime-boost regime of IMVAMUNE® provided complete 
protection from subsequent challenge with monkeypox.  
We played an essential part in providing evidence supporting the licensure an MVA 
derived vaccine against smallpox and monkeypox (Hatch et al., 2013a, Tree et al., 2015, 
Tree et al., 2016). JYNNEOS™ was approved by the US Food and Drug Administration 
(FDA) in September 2019 for the prevention of smallpox and monkeypox in adults. It is 
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the only FDA-approved non-replicating smallpox and monkeypox vaccine and the only 
approved monkeypox vaccine in the world. The vaccine is marketed under the brand 
names IMVANEX® and IMVAMUNE® in the EU and Canada. Recent cases of monkeypox 
virus infection in the UK have used IMVANEX® as part of the national response, and it is 
now used to vaccinate ‘at risk’ staff at PHE. 
1.5. The future  
The expertise I have gained, and the systems developed in the refinement of aerosol 
animal models at high containment continues to be of importance to the PHE goal of 
protecting human health. A large programme of TB vaccine research and testing 
continues, as does research into countermeasures against emerging pathogens and 
potential biowarfare agents. The skills and systems are easily transferrable in the event 
of a required response to a national demand or research objectives. 
PHE is committed to building a high containment in vivo facility when it relocates its 
headquarters and two scientific centres, Porton and Colindale to a new campus at 
Harlow on the former GlaxoSmithKline New Frontiers Science Park. The new build 
facility at PHE Harlow will contain a suited in vivo facility capable of handling animals up 
to ACDP and SAPO Containment Levels 4. This will be a first in the UK and I am the PHE 
Senior User advising the Science Hub programme on high containment in vivo facilities. 
Transition to PHE Harlow is key for my department. The expertise and knowledge I have 
gained working in the development of aerosol models and the challenges around 
handling high consequence pathogens will prove vital in the process. 
1.6. Concluding comments 
This thesis has brought together my published papers, which involve the development 
and use of animal models of a range of pathogens mostly from ACDP hazard group 3. 
The work follows a career that has grown from research technician, through study 
management, to leadership of research and service delivery.  
The improvements in aerosol delivery technology, containment strategies and clinical 
data gathering have all fed into the principles of reduction, refinement and replacement 
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embedded in animal research. The technological and procedural advances introduced 
during my career have positively impacted the way high containment animal studies are 
performed at PHE Porton. We have increased the reproducibility of delivered aerosol 
doses thus enabling reduction of the number of test animals required. Studies have been 
refined by telemetry, advanced CCTV, veterinary blood analysers, radiographs and 
imaging capabilities to both improve euthanasia endpoints, reduce numbers, and make 
best use of the animals. 
The strategies employed have been instrumental in the pre-clinical evaluation of 
vaccines against tuberculosis, the approval of a new vaccine for smallpox, and post-
exposure treatment regimens of anthrax and other diseases in the biodefence arena. 
The last year has seen our in vivo facility largely dedicated to the evaluation of vaccines 
and therapeutics against SARS-CoV-2. The flexible high containment facilities, 
knowledge and skilled staff have enabled PHE to rapidly develop NHP, ferret and 
hamster models of Covid-19 and assist in the UK and worldwide effort to rapidly assess 
the efficacy of new vaccines and therapeutics. 
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